News

Azilsartan medoxomil is a prodrug of the active moiety azilsartan, which lowers blood pressure by blocking the action of a vasopressor hormone, angiotensin II, Takeda said. Azilsartan medoxomil

Salix Pharma and Norway-based specialty pharmaceutical company Photocure have entered into an agreement under which the two companies will collaborate in the development and commercialisation of Lumacan. Lumacan

Pradaxa is an anticoagulant that acts by inhibiting thrombin, an enzyme in the blood that is involved in blood clotting. A clinical trial comparing with the anticoagulant warfarin

The INOVA H3-5 syringe line operates within a Restricted Access Barrier System (RABS) and incorporates the ability to fill under vacuum, which facilitates handling of viscous products and

MKC1106-MT is an active immunotherapeutic treatment consisting of three components, a DNA plasmid encoding select portions of Melan A and tyrosinase (two tumor-specific antigens that are highly expressed

According to ImmuPharma, the study was designed to show safety and tolerability and assess the maximum tolerated dose of IPP-204106. In the trial, the patients were dosed with

Chugai said that the Phase III study was a randomised, double-blind, parallel-group, comparative study to compare the 3-year incidence of bone fractures and the safety of eldecalcitol with

ADL5945, licensed from Eli Lilly and Company in 2009, is a proprietary, peripherally-acting mu opioid receptor antagonist. Adolor plans to recruit about 120 patients in the trial, to

Allist will fund the development costs required for the regulatory approval in China for the two products. Under the agreement, Allist undertakes to perform development activities according to